<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33419478</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2047-9158</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>08</Day></PubDate></JournalIssue><Title>Translational neurodegeneration</Title><ISOAbbreviation>Transl Neurodegener</ISOAbbreviation></Journal><ArticleTitle>Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>3</StartPage><MedlinePgn>3</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40035-020-00228-9</ELocationID><Abstract><AbstractText>Accumulating evidence has suggested that the pathological changes in amyotrophic lateral sclerosis (ALS) are not only confined to the central nervous system but also occur in the peripheral circulating system. Here, we performed a meta-analysis based on the PubMed, EMBASE, EBSCO, and CNKI databases, to find out biochemical indicators associated with energy metabolism, iron homeostasis, and muscle injury that are altered in ALS patients and their correlations with ALS phenotypes. Forty-six studies covering 17 biochemical indicators, representing 5454 ALS patients and 7986 control subjects, were included in this meta-analysis. Four indicators, including fasting blood glucose level (weighted mean difference [WMD] = 0.13, 95% CI [0.06-0.21], p = 0.001), serum ferritin level (WMD = 63.42, 95% CI [48.12-78.73], p &lt;&#x2009;0.001), transferrin saturation coefficient level (WMD = 2.79, 95% CI [1.52-4.05], p &lt;&#x2009;0.001), and creatine kinase level (WMD = 80.29, 95% CI [32.90-127.67], p &lt;&#x2009;0.001), were significantly higher in the ALS patients, whereas the total iron-binding capacity (WMD = -&#x2009;2.42, 95% CI [-&#x2009;3.93, -&#x2009;0.90], p = 0.002) was significantly lower in ALS patients than in the control subjects. In contrast, the other 12 candidates did not show significant differences between ALS patients and controls. Moreover, pooled hazard ratios (HR) showed significantly reduced survival (HR = 1.38, 95% CI [1.02-1.88], p = 0.039) of ALS patients with elevated serum ferritin levels. These findings suggest that abnormalities in energy metabolism and disruption of iron homeostasis are involved in the pathogenesis of ALS. In addition, the serum ferritin level is negatively associated with the overall survival of ALS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Yangfan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yongping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shang</LastName><ForeName>Huifang</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-0947-1151</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurodegenerative Disorders, Rare Disease Center, West China Hospital, Sichuan University, Chengdu, 610041, China. hfshang2002@126.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Clinical Research Center for Geriatric, Laboratory of Neurodegenerative Disorders, West China Hospital, Sichuan University, Chengdu, 610041, China. hfshang2002@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2016YFC0901504</GrantID><Agency>National Key Research and Development Program of China</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transl Neurodegener</MedlineTA><NlmUniqueID>101591861</NlmUniqueID><ISSNLinking>2047-9158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-73-2</RegistryNumber><NameOfSubstance UI="D005293">Ferritins</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005293" MajorTopicYN="N">Ferritins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Biochemical indicators</Keyword><Keyword MajorTopicYN="N">Creatinine kinase</Keyword><Keyword MajorTopicYN="N">Energy homeostasis</Keyword><Keyword MajorTopicYN="N">Iron metabolism</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33419478</ArticleId><ArticleId IdType="pmc">PMC7792103</ArticleId><ArticleId IdType="doi">10.1186/s40035-020-00228-9</ArticleId><ArticleId IdType="pii">10.1186/s40035-020-00228-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2013;955. doi: 10.1016/S0140-6736(10)61156-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2013;172. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(Suppl 1):S3&#x2013;S9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur J Neurol. 2012;19(3):360&#x2013;375. doi: 10.1111/j.1468-1331.2011.03501.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2011.03501.x</ArticleId><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian-Qian W, Yongping C, Bei C, Ru Wei O, Lingyu Z, Yanbing H, et al. Blood hemoglobin A1c levels and amyotrophic lateral sclerosis survival. Mol Neurodegener. 2017;12:1&#x2013;7. doi: 10.1186/s13024-016-0142-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0142-z</ArticleId><ArticleId IdType="pmc">PMC5609007</ArticleId><ArticleId IdType="pubmed">28934974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mariosa D, Hammar N, Malmstr&#xf6;m H, Ingre C, Jungner I, Ye W, et al. Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: a more than 20-year follow-up of the Swedish AMORIS cohort. Ann Neurol. 2017;81(5):718&#x2013;728. doi: 10.1002/ana.24936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24936</ArticleId><ArticleId IdType="pubmed">28437840</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat PF, Bruneteau G, Gordon PH, Dupuis L, Bonnefont-Rousselot D, Simon D, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1&#x2013;2):166&#x2013;171. doi: 10.3109/17482960902822960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902822960</ArticleId><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez De Aguilar JL. Lipid biomarkers for amyotrophic lateral sclerosis. Front Neurol. 2019;10:284. doi: 10.3389/fneur.2019.00284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00284</ArticleId><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Yazdani S, Piehl F, Magnusson PKE, Fang F. Polygenic link between blood lipids and amyotrophic lateral sclerosis. Neurobiol Aging. 2018;67:202.</Citation><ArticleIdList><ArticleId IdType="pubmed">29685649</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Khalik J, Yutuc E, Crick PJ, Gustafsson J, Warner M, Roman G, et al. Defective cholesterol metabolism in amyotrophic lateral sclerosis. J Lipid Res. 2017;58(1):267&#x2013;278. doi: 10.1194/jlr.P071639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.P071639</ArticleId><ArticleId IdType="pmc">PMC5234729</ArticleId><ArticleId IdType="pubmed">27811233</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Bovio G, Canosa A, Bertuzzo D, Galmozzi F, et al. Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: a population-based study. JAMA Neurol. 2014;71(9):1134&#x2013;1142. doi: 10.1001/jamaneurol.2014.1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.1129</ArticleId><ArticleId IdType="pubmed">25048026</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wei QQ, Chen Y, Cao B, Ou R, Hou Y, et al. Clinical disease stage related changes of serological factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(1&#x2013;2):53&#x2013;60. doi: 10.1080/21678421.2018.1550516.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1550516</ArticleId><ArticleId IdType="pubmed">30784318</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Rosi E, Fini N, Fasano A, Raggi S, Fantuzzi A, et al. Changes in routine laboratory tests and survival in amyotrophic lateral sclerosis. Neurol Sci. 2017;38(12):2177&#x2013;2182. doi: 10.1007/s10072-017-3138-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-3138-8</ArticleId><ArticleId IdType="pubmed">28980128</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaldan S, Bush AI, Devos D, Rolland AS, Moreau C. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration. Free Radic Biol Med. 2019;133:221&#x2013;233. doi: 10.1016/j.freeradbiomed.2018.09.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2018.09.033</ArticleId><ArticleId IdType="pubmed">30266679</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Gao L, Wang D, Zang D. Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2017;136(2):145&#x2013;150. doi: 10.1111/ane.12708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.12708</ArticleId><ArticleId IdType="pubmed">27804118</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Allen K, Oei F, Leoni E, Kuhle J, Tree T, et al. Systemic inflammatory response and neuromuscular involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016;3(4):e244. doi: 10.1212/NXI.0000000000000244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000244</ArticleId><ArticleId IdType="pmc">PMC4897985</ArticleId><ArticleId IdType="pubmed">27308305</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D, Hashizume A, Hijikata Y, Yamada S, Iguchi Y, Iida M, et al. Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis. J Neurol. 2019;266(12):2952&#x2013;2961. doi: 10.1007/s00415-019-09507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-019-09507-6</ArticleId><ArticleId IdType="pubmed">31456060</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Dom&#xed;nguez R, Aso E, Povedano M, Ferrer I. Inflammatory gene expression in whole peripheral blood at early stages of sporadic amyotrophic lateral sclerosis. Front Neurol. 2017;8:546. doi: 10.3389/fneur.2017.00546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00546</ArticleId><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt S, Dedeoglu A, Speer O, Wallimann T, Beal MF, Andreassen OA. Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radic Biol Med. 2002;32(9):920&#x2013;926. doi: 10.1016/S0891-5849(02)00784-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(02)00784-0</ArticleId><ArticleId IdType="pubmed">11978494</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000097</ArticleId><ArticleId IdType="pmc">PMC2707599</ArticleId><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. doi: 10.1186/1471-2288-14-135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-135</ArticleId><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken: Wiley; 2019. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119536604.ch12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9781119536604.ch12</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi: 10.1186/1745-6215-8-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1745-6215-8-16</ArticleId><ArticleId IdType="pmc">PMC1920534</ArticleId><ArticleId IdType="pubmed">17555582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittlb&#xf6;ck M, Heinzl H. A simulation study comparing properties of heterogeneity measures in meta-analyses. Stat Med. 2006;25(24):4321&#x2013;4333. doi: 10.1002/sim.2692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.2692</ArticleId><ArticleId IdType="pubmed">16991104</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwig L, Macaskill P, Berry G, Glasziou P. Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ. 1998;316(7129):470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2665595</ArticleId><ArticleId IdType="pubmed">9492687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y, Yang X, Li X, Wang H, Wang T. Elevated cerebrospinal fluid homocysteine is associated with blood-brain barrier disruption in amyotrophic lateral sclerosis patients. Neurol Sci. 2020;41(7):1865&#x2013;1872. doi: 10.1007/s10072-020-04292-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04292-x</ArticleId><ArticleId IdType="pubmed">32086685</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunseich C, Patankar A, Amaya J, Watts JA, Li D, Ramirez P, et al. Clinical and molecular aspects of senataxin mutations in amyotrophic lateral sclerosis 4. Ann Neurol. 2020;87(4):547&#x2013;555. doi: 10.1002/ana.25681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25681</ArticleId><ArticleId IdType="pmc">PMC7818251</ArticleId><ArticleId IdType="pubmed">31957062</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Streich L, Pinto S, Pronto-Laborinho A, Nimtz M, Conradt HS, et al. Exploring cerebrospinal fluid igg n-glycosylation as potential biomarker for amyotrophic lateral sclerosis. Mol Neurobiol. 2019;56(8):5729&#x2013;5739. doi: 10.1007/s12035-019-1482-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-019-1482-9</ArticleId><ArticleId IdType="pubmed">30674035</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikenaka KMDP, Atsuta NMDP, Maeda YP, Hotta YP, Nakamura RMDP, Kawai KP, et al. Increase of arginine dimethylation correlates with the progression and prognosis of ALS. Neurology. 2019;92(16):e1868&#x2013;e1e77. doi: 10.1212/WNL.0000000000007311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007311</ArticleId><ArticleId IdType="pubmed">30867270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Q, Yang F, Wang H, Cui F, Li Y, Li S, et al. Elevated serum ferritin level as a predictor of reduced survival in patients with sporadic amyotrophic lateral sclerosis in China: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3&#x2013;4):186&#x2013;191. doi: 10.1080/21678421.2018.1555599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1555599</ArticleId><ArticleId IdType="pubmed">30652532</ArticleId></ArticleIdList></Reference><Reference><Citation>Lombardi V, Querin G, Ziff OJ, Zampedri L, Martinelli I, Heller C, et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology. 2019;92(11):e1205&#x2013;e1e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6511101</ArticleId><ArticleId IdType="pubmed">30787165</ArticleId></ArticleIdList></Reference><Reference><Citation>Barros A, Dourado MET, Jr, Pedrosa LFC, Leite-Lais L. Association of copper status with lipid profile and functional status in patients with amyotrophic lateral sclerosis. J Nutr Metab. 2018;2018:5678698. doi: 10.1155/2018/5678698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/5678698</ArticleId><ArticleId IdType="pmc">PMC6079445</ArticleId><ArticleId IdType="pubmed">30116640</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol. 2018;265(3):510&#x2013;521. doi: 10.1007/s00415-017-8730-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-017-8730-6</ArticleId><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku&#x142;akowska A, Tarasiuk J, Kapica-Topczewska K, Chor&#x105;&#x17c;y M, Pogorzelski R, Kulczy&#x144;ska-Przybik A, et al. Pathophysiological implications of actin-free Gc-globulin concentration changes in blood plasma and cerebrospinal fluid collected from patients with Alzheimer's disease and other neurological disorders. Adv Clin Exp Med. 2018;27(8):1075&#x2013;1080. doi: 10.17219/acem/70441.</Citation><ArticleIdList><ArticleId IdType="doi">10.17219/acem/70441</ArticleId><ArticleId IdType="pubmed">29905407</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Wang N, Qi F, Wang X, Zhu Q, Lu Y, et al. Serum ferritin is a candidate biomarker of disease aggravation in amyotrophic lateral sclerosis. Biomed Rep. 2018;9(4):333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6142032</ArticleId><ArticleId IdType="pubmed">30233786</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SM, Noh MY, Kim H, Cheon SY, Lee KM, Lee J, et al. 25-Hydroxycholesterol is involved in the pathogenesis of amyotrophic lateral sclerosis. Oncotarget. 2017;8(7):11855&#x2013;11867. doi: 10.18632/oncotarget.14416.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.14416</ArticleId><ArticleId IdType="pmc">PMC5355309</ArticleId><ArticleId IdType="pubmed">28060747</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaye JB, Patin F, Piver E, Bruno C, Vasse M, Vourc'h P, et al. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J Neurol Sci. 2017;380:124&#x2013;127. doi: 10.1016/j.jns.2017.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.07.019</ArticleId><ArticleId IdType="pubmed">28870551</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21(3):104&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Steinacker P, Volk AE, Weishaupt JH, Wollmer MA, Boxer A, et al. Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. J Neural Transm (Vienna) 2016;123(3):289&#x2013;296. doi: 10.1007/s00702-015-1486-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-015-1486-1</ArticleId><ArticleId IdType="pubmed">26659729</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A, Blasco H, Fleury MC, Corcia P, Echaniz-Laguna A, Robelin L, et al. Blood cell palmitoleate-palmitate ratio is an independent prognostic factor for amyotrophic lateral sclerosis. PLoS One. 2015;10(7):e0131512. doi: 10.1371/journal.pone.0131512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0131512</ArticleId><ArticleId IdType="pmc">PMC4492495</ArticleId><ArticleId IdType="pubmed">26147510</ArticleId></ArticleIdList></Reference><Reference><Citation>Su XW, Clardy SL, Stephens HE, Simmons Z, Connor JR. Serum ferritin is elevated in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1/2):102&#x2013;107. doi: 10.3109/21678421.2014.984723.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.984723</ArticleId><ArticleId IdType="pubmed">25521651</ArticleId></ArticleIdList></Reference><Reference><Citation>May C, Nordhoff E, Casjens S, Turewicz M, Eisenacher M, Gold R, et al. Highly immunoreactive IgG antibodies directed against a set of twenty human proteins in the sera of patients with amyotrophic lateral sclerosis identified by protein array. PLoS One. 2014;9(2):e89596. doi: 10.1371/journal.pone.0089596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0089596</ArticleId><ArticleId IdType="pmc">PMC3935926</ArticleId><ArticleId IdType="pubmed">24586901</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A, Acimovic J, L&#xf6;vgren-Sandblom A, Parini P, Andersen PM, Bj&#xf6;rkhem I. Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor. PLoS One. 2014;9(11):e113619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4240598</ArticleId><ArticleId IdType="pubmed">25415378</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2014;383(9934):2065&#x2013;2072. doi: 10.1016/S0140-6736(14)60222-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(14)60222-1</ArticleId><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang R, Guo X, Chen X, Zheng Z, Wei Q, Cao B, et al. The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-West China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5&#x2013;6):359&#x2013;365. doi: 10.3109/21678421.2015.1047454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1047454</ArticleId><ArticleId IdType="pubmed">26121273</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco HPP, Nadal-Desbarats LP, Pradat P-FMDP, Gordon PHMDP, Antar C, Veyrat-Durebex CP, et al. Untargeted 1H-NMR metabolomics in CSF: toward a diagnostic biomarker for motor neuron disease. Neurology. 2014;82(13):1167&#x2013;1174. doi: 10.1212/WNL.0000000000000274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000274</ArticleId><ArticleId IdType="pubmed">24587475</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C, Corcia P, Mucha A, Benzimra S, Mallet C, Gendrot C, et al. Iron metabolism disturbance in a French cohort of ALS patients. Biomed Res Int. 2014;2014:485723. doi: 10.1155/2014/485723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/485723</ArticleId><ArticleId IdType="pmc">PMC4101961</ArticleId><ArticleId IdType="pubmed">25101285</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang JW, Kim SM, Kim HJ, Kim JE, Park KS, Kim SH, et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J Clin Neurol. 2013;9(2):125&#x2013;129. doi: 10.3988/jcn.2013.9.2.125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3988/jcn.2013.9.2.125</ArticleId><ArticleId IdType="pmc">PMC3633190</ArticleId><ArticleId IdType="pubmed">23626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N, Tiloca C, Mencacci NE, Morelli C, Doretti A, Rusconi D, et al. Oligoclonal bands in the cerebrospinal fluid of amyotrophic lateral sclerosis patients with disease-associated mutations. J Neurol. 2013;260(1):85&#x2013;92. doi: 10.1007/s00415-012-6589-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-012-6589-0</ArticleId><ArticleId IdType="pmc">PMC4196642</ArticleId><ArticleId IdType="pubmed">22752089</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501&#x2013;1508. doi: 10.2169/internalmedicine.51.7465.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nadjar Y, Gordon P, Corcia P, Bensimon G, Pieroni L, Meininger V, et al. Elevated serum ferritin is associated with reduced survival in amyotrophic lateral sclerosis. PLoS One. 2012;7(9):1&#x2013;6. doi: 10.1371/journal.pone.0045034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045034</ArticleId><ArticleId IdType="pmc">PMC3443244</ArticleId><ArticleId IdType="pubmed">23024788</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja NA, van der Schouw YT, Fischer K, Sizoo EM, Huisman MH, Veldink JH, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638&#x2013;642. doi: 10.1136/jnnp.2010.236752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2010.236752</ArticleId><ArticleId IdType="pubmed">21471184</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;ssmuth SD, Sperfeld AD, Ludolph AC, Tumani H. Hypercapnia is a possible determinant of the function of the blood-cerebrospinal fluid barrier in amyotrophic lateral sclerosis. Neurochem Res. 2010;35(7):1071&#x2013;1074. doi: 10.1007/s11064-010-0156-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-010-0156-9</ArticleId><ArticleId IdType="pubmed">20333464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell RM, Simmons Z, Beard JL, Stephens HE, Connor JR. Plasma biomarkers associated with ALS and their relationship to iron homeostasis. Muscle Nerve. 2010;42(1):95&#x2013;103. doi: 10.1002/mus.21625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21625</ArticleId><ArticleId IdType="pubmed">20544912</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Ilardi A, Cavallo E, Moglia C, Mutani R, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681&#x2013;1685. doi: 10.1212/WNL.0b013e3181c1df1e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df1e</ArticleId><ArticleId IdType="pubmed">19917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Corcia P, Fergani A, De Aguilar JL, Bonnefont-Rousselot D, Bittar R, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi M, Brown RH, Jr, Rogers JT, Cudkowicz ME. Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis. Open Neurol J. 2008;2:51&#x2013;54. doi: 10.2174/1874205X00802010051.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1874205X00802010051</ArticleId><ArticleId IdType="pmc">PMC2627516</ArticleId><ArticleId IdType="pubmed">19452011</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodall EF, Haque MS, Morrison KE. Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J Neurology. 2008;255(11):1652&#x2013;1656. doi: 10.1007/s00415-008-0945-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-008-0945-0</ArticleId><ArticleId IdType="pubmed">18677636</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohmiya M, Tanaka M, Suzuki Y, Tanino Y, Okamoto K, Yamamoto Y. An increase of oxidized coenzyme Q-10 occurs in the plasma of sporadic ALS patients. J Neurol Sci. 2005;228(1):49&#x2013;53. doi: 10.1016/j.jns.2004.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2004.09.030</ArticleId><ArticleId IdType="pubmed">15607210</ArticleId></ArticleIdList></Reference><Reference><Citation>Yushchenko M, Weber F, M&#xe4;der M, Sch&#xf6;ll U, Maliszewska M, Tumani H, et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol. 2000;110(1&#x2013;2):244&#x2013;251. doi: 10.1016/S0165-5728(00)00339-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(00)00339-8</ArticleId><ArticleId IdType="pubmed">11024556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, Langen KJ, Regard M, Herzog H, Kemper B, Kuwert T, et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand. 1992;85(2):81&#x2013;89. doi: 10.1111/j.1600-0404.1992.tb04003.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0404.1992.tb04003.x</ArticleId><ArticleId IdType="pubmed">1574993</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris MD, Davidson MB, Rosenberg CS. Insulin antagonism is not a primary abnormality of amyotrophic lateral sclerois but is related to disease severity. J Clin Endocrinol Metab. 1986;63(1):41&#x2013;46. doi: 10.1210/jcem-63-1-41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jcem-63-1-41</ArticleId><ArticleId IdType="pubmed">3519649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jockers-Wretou E, Vassilopoulos D. Serum creatine kinase B subunit levels in neurogenic atrophies. J Neurol. 1985;232(4):236&#x2013;239. doi: 10.1007/BF00313786.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00313786</ArticleId><ArticleId IdType="pubmed">4045516</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes ET, Perurena OH, Festoff BW, Jorgensen R, Moore WV. Insulin resistance in amyotrophic lateral sclerosis. J Neurol Sci. 1984;63(3):317&#x2013;324. doi: 10.1016/0022-510X(84)90154-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(84)90154-0</ArticleId><ArticleId IdType="pubmed">6374040</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai A, Miyahara T, Tanaka T, Kaneko T, Sako Y, Kameyama M. Abnormalities of lipoprotein and carbohydrate metabolism in degenerative diseases of the nervous system--motor neuron disease and spinocerebellar degeneration. Tohoku J Exp Med. 1983;139(4):365&#x2013;376. doi: 10.1620/tjem.139.365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1620/tjem.139.365</ArticleId><ArticleId IdType="pubmed">6346585</ArticleId></ArticleIdList></Reference><Reference><Citation>Moxley RT, Griggs RC, Forbes GB, Goldblatt D, Donohoe K. Influence of muscle wasting on oral glucose tolerance testing. Clin Sci (Lond) 1983;64(6):601&#x2013;609. doi: 10.1042/cs0640601.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/cs0640601</ArticleId><ArticleId IdType="pubmed">6340918</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Pradat PF, Ludolph AC, Loeffler JP. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10(1):75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Connor JR. The roles of iron and HFE genotype in neurological diseases. Mol Asp Med. 2020;75:100867. doi: 10.1016/j.mam.2020.100867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2020.100867</ArticleId><ArticleId IdType="pubmed">32654761</ArticleId></ArticleIdList></Reference><Reference><Citation>Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 2009;23(3):95&#x2013;104. doi: 10.1016/j.blre.2008.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2008.08.001</ArticleId><ArticleId IdType="pmc">PMC2717717</ArticleId><ArticleId IdType="pubmed">18835072</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AV, Vyas V, Montani E, Cartelli D, Parazzoli D, Oldani A, et al. Investigation of in vitro cytotoxicity of the redox state of ionic iron in neuroblastoma cells. J Neurosci Rural Pract. 2012;3(3):301&#x2013;310. doi: 10.4103/0976-3147.102611.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0976-3147.102611</ArticleId><ArticleId IdType="pmc">PMC3505322</ArticleId><ArticleId IdType="pubmed">23188983</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio P, Levi S. Ferritin, iron homeostasis, and oxidative damage. Free Radic Biol Med. 2002;33(4):457&#x2013;463. doi: 10.1016/S0891-5849(02)00842-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(02)00842-0</ArticleId><ArticleId IdType="pubmed">12160928</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheykhansari S, Kozielski K, Bill J, Sitti M, Gemmati D, Zamboni P, et al. Redox metals homeostasis in multiple sclerosis and amyotrophic lateral sclerosis: a review. Cell Death Dis. 2018;9(3):348. doi: 10.1038/s41419-018-0379-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0379-2</ArticleId><ArticleId IdType="pmc">PMC5832817</ArticleId><ArticleId IdType="pubmed">29497049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014;6(4):748&#x2013;773. doi: 10.1039/C3MT00347G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1039/C3MT00347G</ArticleId><ArticleId IdType="pubmed">24549403</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganz T, Nemeth E. Iron homeostasis in host defence and inflammation. Nat Rev Immunol. 2015;15(8):500&#x2013;510. doi: 10.1038/nri3863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3863</ArticleId><ArticleId IdType="pmc">PMC4801113</ArticleId><ArticleId IdType="pubmed">26160612</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisato V, Zuliani G, Vigliano M, Longo G, Franchini E, Secchiero P, et al. Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases. PLoS One. 2018;13(3):e0193867. doi: 10.1371/journal.pone.0193867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0193867</ArticleId><ArticleId IdType="pmc">PMC5843269</ArticleId><ArticleId IdType="pubmed">29518107</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemmati D, Zeri G, Orioli E, De Gaetano FE, Salvi F, Bartolomei I, et al. Polymorphisms in the genes coding for iron binding and transporting proteins are associated with disability, severity, and early progression in multiple sclerosis. BMC Med Genet. 2012;13:70. doi: 10.1186/1471-2350-13-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2350-13-70</ArticleId><ArticleId IdType="pmc">PMC3490944</ArticleId><ArticleId IdType="pubmed">22883388</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Cabronero J, Machts J, Schreiber S, Abdulla S, Kollewe K, Petri S, et al. Quantitative susceptibility MRI to detect brain iron in amyotrophic lateral sclerosis. Radiology. 2018;289(1):195&#x2013;203. doi: 10.1148/radiol.2018180112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.2018180112</ArticleId><ArticleId IdType="pmc">PMC6166868</ArticleId><ArticleId IdType="pubmed">30040038</ArticleId></ArticleIdList></Reference><Reference><Citation>Adachi Y, Sato N, Saito Y, Kimura Y, Nakata Y, Ito K, et al. Usefulness of SWI for the detection of iron in the motor cortex in amyotrophic lateral sclerosis. J Neuroimaging. 2015;25(3):443&#x2013;451. doi: 10.1111/jon.12127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jon.12127</ArticleId><ArticleId IdType="pubmed">24888543</ArticleId></ArticleIdList></Reference><Reference><Citation>Golko-Perez S, Amit T, Bar-Am O, Youdim MB, Weinreb O. A novel iron chelator-radical scavenger ameliorates motor dysfunction and improves life span and mitochondrial biogenesis in SOD1(G93A) ALS mice. Neurotox Res. 2017;31(2):230&#x2013;244. doi: 10.1007/s12640-016-9677-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-016-9677-6</ArticleId><ArticleId IdType="pubmed">27826939</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, et al. Could conservative iron chelation lead to neuroprotection in amyotrophic lateral sclerosis? Antioxid Redox Signal. 2018;29(8):742&#x2013;748. doi: 10.1089/ars.2017.7493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2017.7493</ArticleId><ArticleId IdType="pmc">PMC6067092</ArticleId><ArticleId IdType="pubmed">29287521</ArticleId></ArticleIdList></Reference><Reference><Citation>Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, et al. Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm (Vienna) 2020;127(2):189&#x2013;203. doi: 10.1007/s00702-019-02138-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-019-02138-1</ArticleId><ArticleId IdType="pubmed">31912279</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Li C, Chen X, Li S, Shang H. Abnormal serum iron-status indicator changes in amyotrophic lateral sclerosis (ALS) patients: a meta-analysis. Front Neurol. 2020;11:380. doi: 10.3389/fneur.2020.00380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.00380</ArticleId><ArticleId IdType="pmc">PMC7251146</ArticleId><ArticleId IdType="pubmed">32508736</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai H, Cui L, Liu M, Guan Y, Li X, Shen D, et al. Creatine kinase level and its relationship with quantitative electromyographic characteristics in amyotrophic lateral sclerosis. Clin Neurophysiol. 2018;129(5):926&#x2013;930. doi: 10.1016/j.clinph.2018.01.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2018.01.071</ArticleId><ArticleId IdType="pubmed">29550653</ArticleId></ArticleIdList></Reference><Reference><Citation>Linkhart TA, Wilson BW. Appearance of acetylcholinesterase and creatine kinase in plasma of normal chickens after denervation. J Neurol Sci. 1975;26(2):193&#x2013;201. doi: 10.1016/0022-510X(75)90032-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(75)90032-5</ArticleId><ArticleId IdType="pubmed">1176988</ArticleId></ArticleIdList></Reference><Reference><Citation>Borai A, Livingstone C, Abdelaal F, Bawazeer A, Keti V, Ferns G. The relationship between glycosylated haemoglobin (HbA1c) and measures of insulin resistance across a range of glucose tolerance. Scand J Clin Lab Invest. 2011;71(2):168&#x2013;172. doi: 10.3109/00365513.2010.547947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365513.2010.547947</ArticleId><ArticleId IdType="pubmed">21348785</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufr&#xe8;re B, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001;74(3):328&#x2013;334. doi: 10.1093/ajcn/74.3.328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/74.3.328</ArticleId><ArticleId IdType="pubmed">11522556</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis. 2005;2(3&#x2013;4):202&#x2013;207. doi: 10.1159/000089626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089626</ArticleId><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(2):113&#x2013;117. doi: 10.1080/17482960802295192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802295192</ArticleId><ArticleId IdType="pubmed">18792852</ArticleId></ArticleIdList></Reference><Reference><Citation>Daulatzai MA. Cerebral hypoperfusion and glucose hypometabolism: key pathophysiological modulators promote neurodegeneration, cognitive impairment, and Alzheimer's disease. J Neurosci Res. 2017;95(4):943&#x2013;972. doi: 10.1002/jnr.23777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.23777</ArticleId><ArticleId IdType="pubmed">27350397</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>